Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05232032 · ClinicalTrials.gov registry record · Phase 2
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
A Phase 2 study of Depressive Disorder, Major and Anxiety Disorder, sponsored by Mclean Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT05232032: Recruiting Phase 2 study of Depressive Disorder, Major and Anxiety Disorder, sponsored by Mclean Hospital.
NCT05232032 is a Phase 2 study of Depressive Disorder, Major and Anxiety Disorder that is actively recruiting participants, run by Mclean Hospital. The registered enrollment target is 112 participants, below the 240-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05232032, a Phase 2 study of Depressive Disorder, Major and Anxiety Disorder, is actively recruiting participants, sponsored by Mclean Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach/avoidance decision-making in unmedicated individuals with major depressive disorder (MDD) and anxiety disorders. More specifically, the study aims to investigate dysregulation within (1) corticostriatal-midbrain circuitry and (2) nociceptin/orphanin FQ peptide and the nociceptin receptor (NOPR).
Primary Outcome
Diagnostic assessment
Conditions Studied
Interventions
- DEVICE Aversive stimuli
- DRUG Nociceptin Receptor Antagonist
Study Locations (1)
Massachusetts
- Mclean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
What NCT05232032 shows while recruiting
NCT05232032 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 240-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (53% lower).
The record links to 2 conditions, with Depressive Disorder, Major appearing as the primary indexed condition, and to 2 interventions - of which Aversive stimuli is the first listed.
NCT05232032 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05232032 about?
NCT05232032 is a clinical study titled "Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation". The study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach/avoidance decision-making in unmedicated individuals with major depressive disorder (MDD) and anxiety disorders. More specifically, the study aims to investigate dysregulati...
What is the current status of trial NCT05232032?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2025-02-01. Estimated completion is 2026-03-31.
What conditions does trial NCT05232032 study?
This clinical trial studies the following conditions: Depressive Disorder, Major, Anxiety Disorder.
What interventions are being tested in trial NCT05232032?
The interventions under investigation include: Aversive stimuli (DEVICE), Nociceptin Receptor Antagonist (DRUG).
Who is sponsoring clinical trial NCT05232032?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05232032 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05232032's enrollment target sits among peer trials
112 29th of 52 higher than 24 of 52 other Depressive Disorder, Major trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder, Major trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
RECRUITING · Phase 2
-
Individualized Functional Connectivity Targeting in aiTBS for Depression
ACTIVE NOT RECRUITING · Phase 2
-
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
COMPLETED · Phase 2
-
A Safety, Efficacy and Tolerability Study of SEP-225289
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI